Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Urovant Sciences Ltd

(NASDAQ: UROV)
Add to Portfolio
+0.58 (+6.08%)
as of Sep 20, 2019

Last 10.12
Change +0.58 (+6.08%)
Open 9.46
Prev. Close 9.54
Today's Range
9.04
10.33
52wk Range
4.05
14.49
Volume 88,300
Avg Volume 56,545
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
UROV +6.08% +8.00% -13.13%
DJIA -0.59% -0.56% +1.04%
S&P 500 -0.49% -0.26% +2.09%

Key Statistics

Annual EPS -4.00
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 289,450
Weighted Alpha -7.20
Standard Deviation +1.23
Profit Margin N/A
Beta N/A

Growth Rates

YTD +53.57%

Opinion

Sell Hold Buy

Recent Headlines

Urovant Sciences Parent Company, Roivant Sciences, and

BusinessWire via COMTEX - Fri Sep 06, 09:00AM EDT
Urovant Sciences (Nasdaq: UROV) today announced that its parent company, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a non-binding memo(full story)
UROV: 10.12 (+0.58)

Urovant Sciences Appoints James Robinson to its Board

BusinessWire via COMTEX - Wed Mar 06, 08:00AM EST
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson, President and(full story)
UROV: 10.12 (+0.58), ALKS: 21.20 (-0.02)